Q4 2024 Embla Medical hf Earnings Call Transcript
Key Points
- Embla Medical hf (OSSFF) achieved a 6% organic sales growth for the full year 2024, driven by strong performance in prosthetics, neuro products, and patient care segments.
- The company reported a 2% increase in gross profit margin for the quarter, supported by cost reduction initiatives and positive product mix.
- Embla Medical hf (OSSFF) successfully launched several innovative products, including the bionic knee solutions Navi and Icon, which received positive market feedback.
- The acquisition of Your Intents has been integrated well, expanding the company's presence in the neuro orthotics field.
- The company issued a positive guidance for 2025, expecting 5 to 8% organic sales growth and a 20 to 21% EBITA margin, indicating confidence in continued strong performance.
- The fourth quarter organic sales growth was slightly lower at 5%, impacted by strong comparables in the patient care business from 2023.
- Embla Medical hf (OSSFF) faced competitive pressures in the bracing and support business, particularly in the United States, affecting high-volume, commoditized product categories.
- The company experienced a slowdown in some large Asian markets within the APAC region, affecting overall performance.
- There is uncertainty regarding the potential impact of US tariffs on the company's supply chain, particularly concerning production in Mexico and China.
- The patient care segment experienced a 1% decline in organic sales for the fourth quarter, attributed to extraordinary comparisons from the previous year.
Welcome to this implant medical full year result. 2024 presentation.
Today's call is being recorded. If you have any objections to this, please disconnect your line.
All participants will be in a listen-only mode throughout the presentation. And afterwards, there will be an answer question and answer session.
I would like to introduce CEO Sveinn Sölvason and CFO G. Arna Sveinsdottir here. Please begin your presentation.
Thank you very much. Good morning and welcome to the medical conference call where we will review the fourth quarter and full year results for 2024 and President and CEO of and joining me on today's call is our CFO at SWD and Employee America's head of the Master Relations Club Center.
The presentation should take approximately 20 minutes after which there will be an opportunity to ask questions during a Q&A session.
If you can, please go to the next slide as we look back on an eventful 2024 what stands out
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
